ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?

ABCELLERA BIOLG (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research • 18 hours ago

JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies

Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.

Zacks Investment Research • Jun 18, 2026

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

Jazz Pharmaceuticals has signed a research collaboration and licensing agreement with Canada's AbCellera to develop ​T-cell engaging multispecific antibodies for cancer, the ‌companies said on Wednesday.

Reuters • Jun 17, 2026

Is ABCELLERA BIOLG (ABCL) Outperforming Other Medical Stocks This Year?

Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.

Zacks Investment Research • Jun 17, 2026

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

DUBLIN & VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies.

Business Wire • Jun 17, 2026

AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash

AbCellera, an antibody platform behind two authorized COVID-19 therapies, has rebuilt itself into a clinical-stage biotech and is one quarter away from pivotal Phase 2 data on its first wholly-owned. The deeper story is the platform: an integrated, AI-driven discovery engine that mines millions of immune cells rather than designing molecules from scratch, backed by a decade of proprietary wet lab. With more than $650M in liquidity against a roughly $1.6B market cap, investors are paying little more than cash and effectively getting the platform, the pipeline, and ~100 royalty positions.

Seeking Alpha • Jun 17, 2026

Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies.

Benzinga • Jun 17, 2026

AbCellera: Q3 Hot Flashes Data Drop Aside, This Stock Is A Difficult Sell

AbCellera Biologics Inc. remains rated Hold, with valuation concerns outweighing near-term pipeline catalysts despite recent share price volatility. ABCL635, targeting hot flashes, is advancing to a Phase 2 trial with a key data readout expected in Q3, potentially derisking the program. Partnered and proprietary pipeline programs lack momentum, with most assets preclinical or awaiting external funding, limiting near-term revenue visibility.

Seeking Alpha • Jun 9, 2026

Wall Street Analysts Think ABCELLERA BIOLG (ABCL) Could Surge 85.59%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 85.6% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Jun 8, 2026

AbCellera Biologics Inc. (ABCL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

AbCellera Biologics Inc. (ABCL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 5, 2026